The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies
https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.107
Abstract
Objective: to assess the compliance of the actual practice of conducting clinical and economic research with the requirements applicable in the Russian Federation (RF) when including drugs in the Federal Program of High-Cost Nosologies (HCN).
Material and methods. In the CyberLeninka and eLibrary databases, a search was made for clinical and economic studies of medicines included in the HCN list published in the RF in the period from 2011 to June 2021.
Results. Information was obtained on 23 published clinical and economic studies of the effectiveness of drugs, which is less than 30% of all drugs included in the HCN program during the specified period. More than half of the studies of chronic disabling diseases had a modeling horizon of 1 year. The sensitivity analysis of the results in over 1/3 of cases considered only the deviation of the price of the strategies under consideration, and in a quarter of cases it was not carried out at all. Only 4 studies evaluated the increase in quality-adjusted life year, although, for chronic disabling diseases, quality of life is one of the key performance indicators.
Conclusion. In the RF, less than 30% of the results of pharmacoeconomical studies of drugs included in the HCN Program are published, which does not allow to make adequate evaluation of pharmacoeconomical approaches to its formation. To analyze the effectiveness of the tools used in assessing the economic efficiency of expensive medical technologies, a further retrospective research of the studies conducted in the RF is required.
About the Authors
A. S. Kolbin
Pavlov University;
Saint Petersburg State University
Russian Federation
Russian Federation
Dr. Med. Sc., Professor, Chief of Chair of Clinical Pharmacology and Evidence-Based Medicine, 6-8 Lev Tolstoy Str., Saint Petersburg 197022;
Professor, Chair of Clinical Pharmacology, 7-9 Universitetskaya Emb., Saint-Petersburg 199034
Yu. M. Gomon
Pavlov University;
St. George the Martyr City Hospital
Russian Federation
Russian Federation
Dr. Med. Sc., Associate Professor, Chair of Clinical Pharmacology and Evidence-Based Medicine, 6-8 Lev Tolstoy Str., Saint Petersburg 197022;
Clinical Pharmacologist, 1 Severnyy Ave., Saint Petersburg 194354
A. R. Kasimova
Pavlov University;
Vreden National Medical Research Center of Traumatology and Orthopedics
Russian Federation
Russian Federation
MD, PhD, Assistant Professor, Chair of Clinical Pharmacology and Evidence-Based Medicine, Pavlov University; Clinical Pharmacologist,
6-8 Lev Tolstoy Str., Saint Petersburg 197022;
8 Academician Baykov Str., Saint Petersburg 195427
A. A. Kurylev
Pavlov University
Russian Federation
Russian Federation
MD, PhD, Assistant Professor, Chair of Clinical Pharmacology and Evidence-Based Medicine,
6-8 Lev Tolstoy Str., Saint Petersburg 197022
A. E. Bem
Pavlov University
Russian Federation
Russian Federation
MD, PhD, Researcher, Chair of Clinical Pharmacology and Evidence-Based Medicine,
6-8 Lev Tolstoy Str., Saint Petersburg 197022
References
1. Federal Law of 21.11.2011 No. 323-FZ “On the basics of public health protection in the Russian Federation”. Available at: https://base.garant.ru/12191967/ (in Russ.) (accessed 20.07.2021).
2. Federal Law of 03.08.2018 No. 299-FZ “On amendments to the Federal Law “On the basics of public health protection in the Russian Federation”. Available at: https://base.garant.ru/72005588/ (in Russ.) (accessed 20.07.2021).
3. Decree of the Government of the Russian Federation of 12.10.2019 No. 2406-r “On approval of the list of vital and essential medicines for 2020, the list of medicines to provide persons with hemophilia, cystic fibrosis, pituitary nanism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, persons after organ transplantation and (or) tissues, a list of medicines for medical use, including medicines for medical use, appointed by the decision of medical commissions of medical organizations, as well as the minimum range of medicines necessary for the provision of medical care”. Available at: https://base.garant.ru/72861778/ (in Russ.) (accessed 20.07.2021).
4. Decree of the Government of the Russian Federation of 10.12.2018 No. 2738-r “On approval of the list of vital and essential medicines for 2019, as well as lists of medicines for medical use and the minimum range of medicines needed for medical care”. Available at: https://base.garant.ru/72123048/ (in Russ.) (accessed 20.07.2021).
5. Order of the Ministry of Health of the Russian Federation of 15.02.2013 No. 69n “On measures to implement the Decree of the Government of the Russian Federation of 26.04.2012 No. 404 “On approval of the rules for maintaining the Federal Register of persons with hemophilia, cystic fibrosis, pituitary nanism, Gaucher disease, malignant neoplasms of lymphoid, hematopoietic and related tissues, multiple sclerosis, persons after transplantation organs and (or) tissues’. Available at: http://base.garant.ru/70362290/ (in Russ.) (accessed 20.07.2021).
6. Kolbin A.S., Ivanyuk A.B. Innovative medicines and their place in the system of drug provision. Politika i upravleniye v zdravoohranenii / Health Policy and Management. 2011; 1: 57–62 (in Russ.).
7. Decree of the Government of the Russian Federation of 28.08.2014 No. 871 “On approval of the rules for the formation of lists of medicines for medical use and the minimum range of medicines necessary for the provision of medical care”. Available at: https://base.garant.ru/70728348/ (in Russ.) (accessed 20.07.2021).
8. Tolkushin A.G. Сomparative pharmacoeconomic study of drugs that alter the course of multiple sclerosis (avonex, betaferon, rebif, copaxone). FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2008; 1 (1): 18–21 (in Russ.).
9. Evdoshenko E.P., Solodun I.Y., Bashlakova E.E., et al. Budget impact analysis of teriflunomide (Aubagio) proposed inclusion into the programme ‘7 high-cost nosologies’ on the budgets of russian federation federal and regional public authorities in the field of healthcare to ensure treatment of multiple sclerosis patients. Pharmacoeconomics: Theory and Practice. 2016; 4 (2): 39–46 (in Russ.). https://doi.org/10.30809/phe.2.2016.5.
10. Makarova E.I., Kulikov A.Yu. Pharmacoeconomics analysis of the medicinal product Copaxone 40 in treating multiple sclerosis. Pharmacoeconomics: Theory and Practice. 2016; 4 (3): 30–4 (in Russ.).
11. Zyryanov S.K., Dyakov Y.N. A clinical-economic evaluation of alemtuzumab in relapsing-remitting multiple sclerosis. Clinical Pharmacology & Therapeutics. 2017; 26 (2): 93–6 (in Russ.).
12. Avxentyeva M.V., Avxentyev N.A., Frolov M.Yu., Derkach E.V. Pharmacoeconomic analysis of everolimus immunosupressive therapy after renal transplantation. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2015; 8 (1): 7–17 (in Russ.). https://doi.org/10.17749/2070-4909.2015.8.1.007-017.
13. Avxentyev N.A., Derkach E.V., Prokopenko E.I. Pharmacoeconomic analysis of everolimus immunosuppressive therapy for de novo kidney transplant recipients in Russia. Russian Journal of Transplantology and Artificial Organs. 2019; 21 (1): 23–34 (in Russ.). https://doi.org/10.15825/1995-1191-2019-1-23-34.
14. Kolbin A.S., Kurylev A.A., Proscurin M.A., Balykina Yu.E. Economic analysis of tacrolimus prolonged-release after liver transplantation. Klinicheskaya farmakologiya I terapiya / Clinical Pharmacology and Therapy. 2014; 23 (4): 103–8 (in Russ.).
15. Kolbin A.S., Kurylev A.A., Proskurin M.A., Balykina Yu.E. Health economic assessment of antirheumatic drugs in patients with reumathoid arthritis progressed after metotrexate. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2016; 9 (3): 20–8 (in Russ.). https://doi.org/10.17749/2070-4909.2016.9.3.020-028.
16. Zyryanov S.K., Cheberda A.E., Belousov D.Yu. Pharmacoeconomic analysis of Actemra® in first-line treatment of rheumatoid arthritis in the modes of combination and monotherapy. Kachestvennaya klinicheskaya praktika / Good Clinical Practice. 2016; 3: 22–34 (in Russ.).
17. Kolbin A.S., Kurylev A.A., Mishinova S.A., et al. Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis. Kachestvennaya klinicheskaya praktika / Good Clinical Practice. 2020; 1: 23–33 (in Russ.). https://doi.org/10.37489/2588-0519-2020-1-23-33.
18. Sevostyanov V.K., Zholobova E.S. Clinical and economic analysis of the use of genetically engineered biological drugs in the treatment of polyarticular juvenile idiopathic arthritis. Russian Medical Journal. 2017; 25 (19): 1385–90 (in Russ.).
19. Rudakova A.V. Pharmacoeconomic aspects of biologic treatments for rheumatoid arthritis. Medical Technologies. Assessment and Choice. 2012; 2: 30–3 (in Russ.).
20. Goryachev D.V., Erdes Sh.F., Nasonov E.L. Pharmacoeconomic analysis of the use of tocilizumab in therapy for rheumatoid arthritis: imitation simulation. Scientific and Practical Rheumatology. 2010; 48 (20): 87–102 (in Russ.).
21. Kulikov A.Yu., Kostina E.O. Pharmacoeconomic evaluation of drugs used in enzyme replacement therapy in the treatment of mucopolysaccharidosis type II. Pharmacoeconomics: Theory and Practice. 2019; 7 (2): 10–5 (in Russ.). https://doi.org/10.30809/phe.2.2019.2.
22. Melik-Guseinov D.V. Budget impact of using recombinant coagulation factor VIII in patients with hemophilia A. Pharmacoeconomics: Theory and Practice. 2015; 3 (3): 118–22 (in Russ.).
23. Avxentyev N.A., Derkach E.V., Makarov A.S. Clinical and economic study of daratumumab in combination therapy for previously treated patients with multiple myeloma. Medical Technologies. Assessment and Choice. 2019; 4: 62–75 (in Russ.). https://doi.org/10.31556/2219-0678.2019.38.4.062-075.
24. Frolov M.Yu., Shatalova O.V. Pharmacoeconomic evaluation of pomalidomide (Imnovid) for the treatment of recurrent and refractory multiple myeloma. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2017; 10 (2): 53–61 (in Russ.). https://doi.org/10.17749/2070-4909.2017.10.2.053-061.
25. Kulikov A.U., Protsenko M.V. Pharmacoeconomic analysis of dasatinib as a second-line therapy in patients with chronic myelogenous leukemia. Pharmacoeconomics: Theory and Practice. 2015; 3 (2): 88– 91 (in Russ.).
26. Kulikov A.Yu., Rybchenko Yu.V. Pharmacoeconomic analysis to compare subcutaneous versus intravenous Mabthera® (rituximab) in patients with follicular lymphoma. Pharmacoeconomics: Theory and Practice. 2015; 3 (2): 14–6 (in Russ.).
27. Yagudina R.I., Zinchuk I.Yu. Pharmacoeconomic analysis of antiinhibitor coagulant complex (AICC) in the treatment of inhibitor hemophilia. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2013; 6 (4): 7–12 (in Russ.).
28. Yagudina R., Kulikov A., Misikova B. Pharmacoeconomical evaluation of multiple myeloma treatment with Revlimid (lenalidomide) in the Russian Federation. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2012; 5 (1): 13–9 (in Russ.).
29. Rudakova A.V. Effectiveness of expenditure for bendamustine treatment of indolent non-hodgkin lymphomas. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2011; 4 (3): 23–7 (in Russ.).
30. Kulikov A.Y., Tishchenko D.G. Pharmacoeconomic evaluation of pomalidomide (Imnovid) use in treatment of patients with relapsed or refractory multiple myeloma who have received at least two lines of therapy comprising lenalidomide and bortezomib. Pharmacoeconomics: Theory and Practice. 2016; 4 (1): 148–56 (in Russ.).
31. Lloyd-Williams H. A systematic review of economic evaluations of advanced therapy medicinal products. Br J Clin Pharmacol. 2021; 87 (6): 2428–43. https://doi.org/10.1111/bcp.14275.
Review
For citations:
Kolbin A.S., Gomon Yu.M., Kasimova A.R., Kurylev A.A., Bem A.E. The real practice of clinical and economic research of drugs included in the Federal Program of High-Cost Nosologies. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):87-105. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.107
Views:
1001
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 